MONDAY, Jan. 23, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was based on data from the phase 3 ALPINE trial, a head-to-head comparison of BTK inhibitors. Patients were randomly assigned to zanubrutinib or ibrutinib. Ibrutinib is a first-generation BTK inhibitor and the current standard treatment.
Jennifer R. Brown, M.D., Ph.D., from Dana-Farber Cancer Institute in Boston, led the ALPINE trial that found zanubrutinib-treated patients had a longer progression-free survival (PFS) at 29.6 months of follow-up (79.5 versus 67.3 percent). Furthermore, patients taking zanubrutinib had a lower rate of treatment discontinuation (26.3 versus 41.2 percent), including for heart disorders and cardiac events. The rate of atrial fibrillation or atrial flutter was lower with zanubrutinib (5.2 percent) versus ibrutinib (13.3 percent).
People are also reading…
The FDA reported that the most common adverse reactions seen with zanubrutinib were a decrease in neutrophil count, upper respiratory tract infection, decrease in platelet count, hemorrhage, and musculoskeletal pain.
“I am encouraged that zanubrutinib has been approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma and optimistic that many patients across the country will benefit from this approval,” Brown said in a statement. “Our findings also found that zanubrutinib led to fewer side effects and adverse events than ibrutinib, leading to a better quality of life for patients.”
Approval of Brukinsa (zanubrutinib) was granted to BeiGene.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
